PD-L1 anticorps (Extracellular Domain) (Biotin)

N° du produit ABIN6992233

Cet anticorps Souris Monoclonal détecte spécifiquement PD-L1 dans ELISA. Il présente une réactivité envers Humain.

Aperçu rapide pour PD-L1 anticorps (Extracellular Domain) (Biotin) (ABIN6992233)

Antigène: PD-L1 (CD274 (PD-L1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-L1 est conjugé à/à la Biotin

Application: ELISA

Clone: 8E12

Détail du produit anti-PD-L1 anticorps (Biotin)

Épitope: Extracellular Domain

Purification: PD-L1 Antibody is supplied as protein A purified IgG1.

Immunogène: PD-L1 antibody was raised against the extracellular domain of human PD-L1.

Isotype: IgG1

Information d'application

Indications d'application: PD-L1 antibody can be used for as detection antibody in Sandwich Elisa at 1 μ,g/mL.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PD-L1 Antibody is supplied in PBS containing 1 % BSA and 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,4 °C

Stockage commentaire: PD-L1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PDL1

Sujet: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

ID gène: 29126

NCBI Accession: NP_054862

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints